NASDAQ:ONS - Oncobiologics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$0.97 -0.02 (-2.02 %)
(As of 05/21/2018 04:00 PM ET)
Previous Close$0.99
Today's Range$0.95 - $1.00
52-Week Range$0.78 - $2.30
Volume18,300 shs
Average Volume37,220 shs
Market Capitalization$32.04 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.07

About Oncobiologics (NASDAQ:ONS)

Oncobiologics logoOncobiologics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, manufacturing, and commercializing complex biosimilar therapeutics in immunology and oncology disease areas. Its advanced product candidate is ONS-3010, an adalimumab biosimilar that is in a Phase 1 clinical trial, which targets the tumor necrosis factor alpha. The company also develops ONS-1045, a bevacizumab biosimilar, which is in a Phase 1 clinical trial that interferes with tumor growth by binding to vascular endothelial growth factor, a protein that stimulates the formation of new blood vessels. Its advanced preclinical product candidate is ONS-1050, a trastuzumab biosimilar, interferes with the human epidermal growth factor receptor 2, a protein that stimulates cell proliferation. Oncobiologics, Inc. has collaboration and license agreements with Selexis SA; IPCA Laboratories Limited; Laboratories Liomont, S.A. de C.V.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was founded in 2010 and is headquartered in Cranbury, New Jersey.

Receive ONS News and Ratings via Email

Sign-up to receive the latest news and ratings for ONS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ONS
CUSIPN/A
Phone609-619-3990

Debt

Debt-to-Equity Ratio-0.10
Current Ratio0.22
Quick Ratio0.22

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$3.81 million
Price / Sales8.23
Cash FlowN/A
Price / CashN/A
Book Value($1.36) per share
Price / Book-0.71

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$-38,840,000.00
Net Margins-445.20%
Return on EquityN/A
Return on Assets-116.68%

Miscellaneous

Employees48
Outstanding Shares32,330,000

Oncobiologics (NASDAQ:ONS) Frequently Asked Questions

What is Oncobiologics' stock symbol?

Oncobiologics trades on the NASDAQ under the ticker symbol "ONS."

Who are some of Oncobiologics' key competitors?

Who are Oncobiologics' key executives?

Oncobiologics' management team includes the folowing people:
  • Dr. Pankaj Mohan, Founder, Chairman, Pres & CEO (Age 53)
  • Mr. Lawrence A. Kenyon, CFO, Principal Accounting Officer & Corp. Sec. (Age 52)
  • Dr. Kenneth M. Bahrt, Chief Medical Officer (Age 65)
  • Rick Gregory, Director of Marketing & Communications
  • Dr. Stephen J. McAndrew, Sr. VP of Bus. Strategy & Devel. (Age 64)

When did Oncobiologics IPO?

(ONS) raised $35 million in an initial public offering (IPO) on Friday, May 13th 2016. The company issued 5,800,000 shares at a price of $6.00 per share. Jefferies and Barclays served as the underwriters for the IPO and Cantor Fitzgerald & Co. was co-manager.

Has Oncobiologics been receiving favorable news coverage?

News articles about ONS stock have trended somewhat positive this week, according to Accern Sentiment. The research group identifies positive and negative press coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Oncobiologics earned a daily sentiment score of 0.12 on Accern's scale. They also assigned press coverage about the company an impact score of 46.60 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.

How do I buy shares of Oncobiologics?

Shares of ONS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Oncobiologics' stock price today?

One share of ONS stock can currently be purchased for approximately $0.97.

How big of a company is Oncobiologics?

Oncobiologics has a market capitalization of $32.04 million and generates $3.81 million in revenue each year. Oncobiologics employs 48 workers across the globe.

How can I contact Oncobiologics?

Oncobiologics' mailing address is 7 CLARKE DRIVE, CRANBURY NJ, 08512. The company can be reached via phone at 609-619-3990 or via email at [email protected]


MarketBeat Community Rating for Oncobiologics (ONS)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  72 (Vote Outperform)
Underperform Votes:  69 (Vote Underperform)
Total Votes:  141
MarketBeat's community ratings are surveys of what our community members think about Oncobiologics and other stocks. Vote "Outperform" if you believe ONS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ONS will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Oncobiologics (NASDAQ:ONS) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
1 Wall Street analysts have issued ratings and price targets for Oncobiologics in the last 12 months. There are currently 1 hold rating for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldBuy
Consensus Rating Score: 2.002.002.332.50
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: N/AN/A$9.00$9.00
Price Target Upside: N/AN/A650.00% upside339.02% upside

Oncobiologics (NASDAQ:ONS) Consensus Price Target History

Price Target History for Oncobiologics (NASDAQ:ONS)

Oncobiologics (NASDAQ:ONS) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/29/2018BarclaysDowngradeOverweight ➝ Equal WeightLowView Rating Details
4/13/2017Cantor FitzgeraldReiterated RatingBuy$15.00LowView Rating Details
4/12/2017Jefferies GroupReiterated RatingHold$3.00HighView Rating Details
(Data available from 5/21/2016 forward)

Earnings

Oncobiologics (NASDAQ:ONS) Earnings History and Estimates Chart

Earnings by Quarter for Oncobiologics (NASDAQ:ONS)

Oncobiologics (NASDAQ ONS) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/14/2018Q1 2018($0.28)$0.77 millionViewN/AView Earnings Details
8/14/2017Q3 2017($0.37)$0.30 millionViewN/AView Earnings Details
5/15/2017Q2 2017($0.80)($0.42)$1.10 million$0.30 millionViewN/AView Earnings Details
2/14/2017Q1 2017($0.79)$0.50 million$0.30 millionViewN/AView Earnings Details
8/15/2016Q3 2016($0.38)($1.60)$0.50 millionViewN/AView Earnings Details
6/27/2016Q2 2016($0.41)($0.32)$1.00 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Oncobiologics (NASDAQ:ONS) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Oncobiologics (NASDAQ ONS) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 33.50%
Institutional Ownership Percentage: 14.49%
Insider Trading History for Oncobiologics (NASDAQ:ONS)
Institutional Ownership by Quarter for Oncobiologics (NASDAQ:ONS)

Oncobiologics (NASDAQ ONS) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/4/2018Pankaj MohanCEOSell114,677$1.17$134,172.09View SEC Filing  
12/22/2017Elizabeth A. YamashitaVPSell16,170$1.13$18,272.10View SEC Filing  
12/22/2017Lawrence A. KenyonCFOSell26,165$1.13$29,566.45View SEC Filing  
12/22/2017Stephen J McandrewSVPSell15,705$1.13$17,746.65View SEC Filing  
12/19/2017Elizabeth A. YamashitaVPSell7,660$1.15$8,809.00View SEC Filing  
12/19/2017Pankaj MohanCEOSell104,131$1.15$119,750.65View SEC Filing  
11/11/2016Scott A. GangloffSVPSell37,369$3.75$140,133.75View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Oncobiologics (NASDAQ ONS) News Headlines

Source:
DateHeadline
Zacks: Oncobiologics (ONS) Receives Consensus Rating of "Hold" from BrokeragesZacks: Oncobiologics (ONS) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - May 17 at 9:18 PM
Oncobiologics Reports Second Quarter Financial Results for Fiscal 2018Oncobiologics Reports Second Quarter Financial Results for Fiscal 2018
finance.yahoo.com - May 16 at 10:25 AM
BRIEF-Oncobiologics Announces $15 Mln Private Placement OfferingBRIEF-Oncobiologics Announces $15 Mln Private Placement Offering
www.reuters.com - May 14 at 11:11 AM
Oncobiologics secures $15M capital raise; shares down 5%Oncobiologics secures $15M capital raise; shares down 5%
seekingalpha.com - May 14 at 11:11 AM
Oncobiologics Announces $15 Million Private Placement OfferingOncobiologics Announces $15 Million Private Placement Offering
finance.yahoo.com - May 14 at 11:11 AM
Oncobiologics (ONS) Lifted to "Hold" at ValuEngineOncobiologics (ONS) Lifted to "Hold" at ValuEngine
www.americanbankingnews.com - May 2 at 10:58 PM
Zacks: Oncobiologics (ONS) Given Average Recommendation of "Hold" by AnalystsZacks: Oncobiologics (ONS) Given Average Recommendation of "Hold" by Analysts
www.americanbankingnews.com - May 2 at 9:58 PM
Zacks Investment Research Downgrades Oncobiologics (ONS) to HoldZacks Investment Research Downgrades Oncobiologics (ONS) to Hold
www.americanbankingnews.com - April 17 at 8:43 PM
Oncobiologics Appoints Randy Thurman to Board of DirectorsOncobiologics Appoints Randy Thurman to Board of Directors
finance.yahoo.com - April 17 at 10:02 AM
 Oncobiologics (ONS) Receives Consensus Recommendation of "Hold" from Analysts Oncobiologics (ONS) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - April 16 at 5:19 AM
Why Oncobiologics Inc’s (NASDAQ:ONS) Ownership Structure Is ImportantWhy Oncobiologics Inc’s (NASDAQ:ONS) Ownership Structure Is Important
finance.yahoo.com - April 11 at 10:44 AM
 Oncobiologics Inc (ONS) Given Average Recommendation of "Hold" by Analysts Oncobiologics Inc (ONS) Given Average Recommendation of "Hold" by Analysts
www.americanbankingnews.com - March 30 at 1:24 PM
Oncobiologics Appoints Dr. Joerg Windisch to Board of DirectorsOncobiologics Appoints Dr. Joerg Windisch to Board of Directors
finance.yahoo.com - March 27 at 10:11 AM
Is Oncobiologics Inc (NASDAQ:ONS) Excessively Paying Its CEO?Is Oncobiologics Inc (NASDAQ:ONS) Excessively Paying Its CEO?
finance.yahoo.com - March 22 at 4:22 PM
 Oncobiologics Inc (ONS) Receives Average Recommendation of "Hold" from Analysts Oncobiologics Inc (ONS) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - March 15 at 5:20 AM
Zacks: Oncobiologics Inc (ONS) Given $11.00 Average Target Price by AnalystsZacks: Oncobiologics Inc (ONS) Given $11.00 Average Target Price by Analysts
www.americanbankingnews.com - March 9 at 1:10 AM
 Brokerages Set $11.00 Target Price for Oncobiologics Inc (ONS) Brokerages Set $11.00 Target Price for Oncobiologics Inc (ONS)
www.americanbankingnews.com - February 27 at 1:24 PM
 Oncobiologics Inc (ONS) Receives Consensus Recommendation of "Hold" from Analysts Oncobiologics Inc (ONS) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - February 21 at 9:24 PM
Want To Invest In Oncobiologics Inc (NASDAQ:ONS)? Here’s How It Performed LatelyWant To Invest In Oncobiologics Inc (NASDAQ:ONS)? Here’s How It Performed Lately
finance.yahoo.com - February 19 at 3:58 PM
Zacks: Oncobiologics Inc (ONS) Given Consensus Rating of "Hold" by BrokeragesZacks: Oncobiologics Inc (ONS) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - February 18 at 7:20 PM
BRIEF-Oncobiologics Inc Files For Resale Of Up To 3.9 Million SharesBRIEF-Oncobiologics Inc Files For Resale Of Up To 3.9 Million Shares
www.reuters.com - February 16 at 9:29 AM
Oncobiologics Reports First Quarter Fiscal Year 2018 ResultsOncobiologics Reports First Quarter Fiscal Year 2018 Results
finance.yahoo.com - February 14 at 3:22 PM
What You Must Know About Oncobiologics Inc’s (NASDAQ:ONS) Major InvestorsWhat You Must Know About Oncobiologics Inc’s (NASDAQ:ONS) Major Investors
finance.yahoo.com - February 14 at 6:10 AM
Oncobiologics Receives Positive Nasdaq Listing DeterminationOncobiologics Receives Positive Nasdaq Listing Determination
finance.yahoo.com - February 14 at 6:10 AM
Zacks: Oncobiologics Inc (ONS) Given Consensus Recommendation of "Hold" by AnalystsZacks: Oncobiologics Inc (ONS) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - February 10 at 3:12 PM
Oncobiologics Announces Term Extension of Series A WarrantsOncobiologics Announces Term Extension of Series A Warrants
finance.yahoo.com - February 9 at 3:27 PM
 Analysts Set $11.00 Price Target for Oncobiologics Inc (ONS) Analysts Set $11.00 Price Target for Oncobiologics Inc (ONS)
www.americanbankingnews.com - February 7 at 11:42 PM
Oncobiologics (ONS) Stock Rating Upgraded by ValuEngineOncobiologics (ONS) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - February 4 at 6:36 PM
Zacks: Analysts Set $11.00 Target Price for Oncobiologics Inc (ONS)Zacks: Analysts Set $11.00 Target Price for Oncobiologics Inc (ONS)
www.americanbankingnews.com - February 2 at 7:08 PM
Oncobiologics (ONS) Stock Rating Lowered by BarclaysOncobiologics (ONS) Stock Rating Lowered by Barclays
www.americanbankingnews.com - January 29 at 7:00 PM
Zacks: Oncobiologics Inc (ONS) Receives Consensus Recommendation of "Strong Buy" from AnalystsZacks: Oncobiologics Inc (ONS) Receives Consensus Recommendation of "Strong Buy" from Analysts
www.americanbankingnews.com - January 25 at 3:14 PM
Comparing Oncobiologics (ONS) & Intrexon (XON)Comparing Oncobiologics (ONS) & Intrexon (XON)
www.americanbankingnews.com - January 22 at 9:10 PM
Critical Analysis: Oncobiologics (ONS) & Organovo (ONVO)Critical Analysis: Oncobiologics (ONS) & Organovo (ONVO)
www.americanbankingnews.com - January 20 at 5:26 AM
Oncobiologics (ONS) & RXi Pharmaceuticals (RXII) Head-To-Head ContrastOncobiologics (ONS) & RXi Pharmaceuticals (RXII) Head-To-Head Contrast
www.americanbankingnews.com - January 16 at 5:08 PM
Zacks: Oncobiologics Inc (ONS) Receives Consensus Rating of "Strong Buy" from AnalystsZacks: Oncobiologics Inc (ONS) Receives Consensus Rating of "Strong Buy" from Analysts
www.americanbankingnews.com - January 9 at 8:12 AM
Pankaj Mohan Sells 114,677 Shares of Oncobiologics Inc (ONS) StockPankaj Mohan Sells 114,677 Shares of Oncobiologics Inc (ONS) Stock
www.americanbankingnews.com - January 5 at 6:50 PM
Oncobiologics (ONS) & The Competition Head-To-Head ReviewOncobiologics (ONS) & The Competition Head-To-Head Review
www.americanbankingnews.com - January 4 at 3:28 PM
Stephen J. Mcandrew Sells 15,705 Shares of Oncobiologics Inc (ONS) StockStephen J. Mcandrew Sells 15,705 Shares of Oncobiologics Inc (ONS) Stock
www.americanbankingnews.com - December 28 at 5:56 PM
Insider Selling: Oncobiologics Inc (ONS) CFO Sells 26,165 Shares of StockInsider Selling: Oncobiologics Inc (ONS) CFO Sells 26,165 Shares of Stock
www.americanbankingnews.com - December 26 at 6:20 PM
Elizabeth A. Yamashita Sells 16,170 Shares of Oncobiologics Inc (ONS) StockElizabeth A. Yamashita Sells 16,170 Shares of Oncobiologics Inc (ONS) Stock
www.americanbankingnews.com - December 26 at 6:20 PM
 Oncobiologics Inc (ONS) Given $11.00 Consensus Price Target by Analysts Oncobiologics Inc (ONS) Given $11.00 Consensus Price Target by Analysts
www.americanbankingnews.com - December 25 at 10:06 AM
 Oncobiologics Inc (ONS) Given Consensus Rating of "Strong Buy" by Analysts Oncobiologics Inc (ONS) Given Consensus Rating of "Strong Buy" by Analysts
www.americanbankingnews.com - December 22 at 12:20 AM
Insider Selling: Oncobiologics Inc (ONS) CEO Sells 104,131 Shares of StockInsider Selling: Oncobiologics Inc (ONS) CEO Sells 104,131 Shares of Stock
www.americanbankingnews.com - December 20 at 8:58 PM
Critical Review: Oncobiologics (ONS) & Its RivalsCritical Review: Oncobiologics (ONS) & Its Rivals
www.americanbankingnews.com - December 16 at 11:08 PM
Is Oncobiologics Inc’s (NASDAQ:ONS) CEO Paid Enough To Stay Motivated?Is Oncobiologics Inc’s (NASDAQ:ONS) CEO Paid Enough To Stay Motivated?
finance.yahoo.com - December 14 at 5:15 PM
 Oncobiologics Inc (ONS) Given $11.00 Average Target Price by Brokerages Oncobiologics Inc (ONS) Given $11.00 Average Target Price by Brokerages
www.americanbankingnews.com - December 6 at 9:38 PM
Does Oncobiologics Inc’s (ONS) Recent Track Record Look Strong?Does Oncobiologics Inc’s (ONS) Recent Track Record Look Strong?
finance.yahoo.com - December 5 at 11:53 AM
Zacks: Oncobiologics, Inc. (ONS) Receives Consensus Recommendation of "Strong Buy" from BrokeragesZacks: Oncobiologics, Inc. (ONS) Receives Consensus Recommendation of "Strong Buy" from Brokerages
www.americanbankingnews.com - November 21 at 9:52 AM
Is Oncobiologics Inc (ONS) Thriving Or Barely Surviving In The Healthcare Sector?Is Oncobiologics Inc (ONS) Thriving Or Barely Surviving In The Healthcare Sector?
finance.yahoo.com - November 20 at 1:55 AM
Zacks: Oncobiologics, Inc. (ONS) Given Consensus Rating of "Strong Buy" by AnalystsZacks: Oncobiologics, Inc. (ONS) Given Consensus Rating of "Strong Buy" by Analysts
www.americanbankingnews.com - November 16 at 3:36 PM

SEC Filings

Oncobiologics (NASDAQ:ONS) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Oncobiologics (NASDAQ:ONS) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Oncobiologics (NASDAQ ONS) Stock Chart for Monday, May, 21, 2018

Loading chart…

This page was last updated on 5/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.